{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-031128","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.541937+00:00","generated_at":"2026-06-13T14:13:33.377254+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pyxis Oncology expands board to 7, appoints Dr. Jakob Dupont as director contingent on Apexigen merger","bullets":["Board size increased to seven members, effective upon closing of merger with Apexigen.","Dr. Jakob Dupont appointed as Class III director, term expiring at 2024 annual meeting.","Dr. Dupont executed voting agreement to support merger proposals; no other arrangements or family ties.","Appointment contingent on merger completion; Dr. Dupont eligible for non-employee director compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-031128","json":"https://secwatch.observer/filing/0000950170-23-031128.json","markdown":"https://secwatch.observer/filing/0000950170-23-031128.md","text":"https://secwatch.observer/filing/0000950170-23-031128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023031128/0000950170-23-031128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023031128/pyxs-20230628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:13:33.377254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6eb646b6c3","claim":"Jakob Dupont was appointed as Director at Pyxis Oncology, Inc..","evidence_excerpt":"the Board also approved on a prospective basis the appointment of Jakob Dupont, M.D. as a director of the Company to fill the vacancy created by that action.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023031128/0000950170-23-031128-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}